Review
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3843-3849
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3843
Table 1 Treatment response and survival rate of hepatic arterial infusion chemotherapy
GroupNo.Treatment regimenResponse rate (CR + PR)Median survival
Toyoda et al[20]21Cisplatin: 5-10 mg 5-FU: 500 mg14.3%36-549 d
Sumie et al[21]16Group 1: Cisplatin 10 mg + 5-FU : 250 mg (5 d)56.3%2.7 yr
21Group 2: TACE with epirubicin23.8%1.7 yr
Kim et al[22]36Group 1: 5-FU 500 mg/m2 on D 1-3 + Cisplatin 60 mg/m2 on D216.7% (PR16.7%)193 d
31Group 2: TACE with doxorubicin (10-60 mg)0%119 d
Hamada et al[23]88Cisplatin: 10 mg 5-FU: 1000 mg17% (CR1%/PR16%)19.5 mo
Lin et al[24]53Cisplatin: 10 mg, 5-FU 100 mg, Mitomycin 2 mg Leucovorin 15 mg28.3%NA
Hwang et al[25]185-FU 330 mg/m2 every week Epirubicin 30 mg/m2 Mitomycin-C 2.7 mg/m2 every 2 wk38.9% (PR 38.9%)8 mo
Sim et al[30]67Group 1: Cisplatin: 80 mg/m2 (1 d)20% (CR2.5%/PR17.5%)5 mo
36Group 2: Cisplatin: 60 mg/m2 (1 d) + 5-FU 500 mg/m2 (3 d)19.2% (CR 3.8%/PR15.4%)8.5 mo
Lim et al[31]40Group 1: Cisplatin 10 mg + 5-FU 250 mg (5 d)3.8%(PR 3.8%)5 mo
39Group 2: Conservative care0%3 mo
Woo et al[26]36Group 1 (High dose): 5-FU 500 mg/m2 on D 1-3 + Cisplatin 60 mg/m2 on D216.7% (PR 16.7%)193 d
32Group 2 (Low dose): 5-FU 170 mg/m2 on D 1-5 + Cisplatin 7 mg/m2 on D 1-50%153 d
Yamashita et al[27]57Group 1 (IFN/FU): 5-FU 300 mg/m2 per day for 5 d for 1st 2 wk + IFNα-2b 3M U IM 3 times/wk for 4 wk45.6% (CR 1.7%/PR 43.9%)10.5 mo
57Group 2 (IFN/FU + Cisplatin): IFN/FU + Cisplatin 20 mg/m2 on day 1, 824.6% (CR 5.3%/PR 19.3%)17.6 mo
Nouso et al[28]476Group 1: Cisplatin + 5-FU40.5%14.0 mo
1466Group 2: No therapy(CR 4.0%/PR 36.5%)5.2 mo
Song et al[29]50Group 1: Cisplatin + 5-FU ± epirubicin24.0%7.1 mo
60Group 2: Sorafenib13.3%5.5 mo